Semaglutide + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis
Conditions
Non-alcoholic Steatohepatitis
Trial Timeline
Apr 1, 2021 → Apr 25, 2029
NCT ID
NCT04822181About Semaglutide + Placebo
Semaglutide + Placebo is a phase 3 stage product being developed by Novo Nordisk for Non-alcoholic Steatohepatitis. The current trial status is active. This product is registered under clinical trial identifier NCT04822181. Target conditions include Non-alcoholic Steatohepatitis.
What happened to similar drugs?
0 of 3 similar drugs in Non-alcoholic Steatohepatitis were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06041217 | Phase 3 | Completed |
| NCT05726227 | Phase 3 | Active |
| NCT05891496 | Phase 3 | Completed |
| NCT05486065 | Phase 2 | Completed |
| NCT04889183 | Phase 3 | Completed |
| NCT04979130 | Approved | Completed |
| NCT04822181 | Phase 3 | Active |
| NCT03842202 | Phase 1 | Completed |
| NCT03548987 | Phase 3 | Completed |
| NCT03357380 | Phase 1 | Completed |
| NCT03086330 | Phase 3 | Completed |
| NCT02692716 | Phase 3 | Completed |
| NCT02970942 | Phase 2 | Completed |
| NCT02906930 | Phase 3 | Completed |
| NCT02827708 | Phase 3 | Completed |
| NCT02773381 | Phase 1 | Completed |
| NCT02557620 | Phase 1 | Completed |
| NCT02305381 | Phase 3 | Completed |
| NCT02212067 | Phase 1 | Completed |
| NCT02161588 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis